(Total Views: 1104)
Posted On: 04/16/2025 9:38:43 PM
Post# of 154604
Huge from WH on PBM middlemen:
The Order builds off that critical work and reevaluates the role of middlemen by:
Improving disclosure of fees that pharmaceutical benefit managers (PBMs) pay to brokers for steering employers to utilize their services.
Directing the administration to develop reforms to promote a more competitive, transparent, efficient, and resilient prescription drug value chain.
By addressing the influence of middlemen and promoting open competition, President Trump’s actions aim to create a fairer prescription drug market that lowers costs and ensures accountability across the health care system.
https://www.whitehouse.gov/fact-sheets/2025/0...ug-prices/
There it is -- a huge issue being addressed & from what posts/articles I've read over last years, the PBM's are a huge piece of the puzzle of drugs prescribed for favor, etc.. --- Mark Cuban even talks about these middle men & his drug company price transparency. He says pricing transparency is #1 issue
Have posted several times with all of the ancillary benefits Leronlimab brings to the table --- Cytodyn advantages are so abundant, no need to "price gouge", ever. Again, we can not be priced out of a disease by a "competitor".
The world is going to love Cytodyn upon realizing LL & LL-PLS pricing to benefits, & Vs others.
No other non-toxic, non death inducing drug for any disease indication like our Leronlimab.
Ladies of Leronlimab MOA is the starting point.
May.
The Order builds off that critical work and reevaluates the role of middlemen by:
Improving disclosure of fees that pharmaceutical benefit managers (PBMs) pay to brokers for steering employers to utilize their services.
Directing the administration to develop reforms to promote a more competitive, transparent, efficient, and resilient prescription drug value chain.
By addressing the influence of middlemen and promoting open competition, President Trump’s actions aim to create a fairer prescription drug market that lowers costs and ensures accountability across the health care system.
https://www.whitehouse.gov/fact-sheets/2025/0...ug-prices/
There it is -- a huge issue being addressed & from what posts/articles I've read over last years, the PBM's are a huge piece of the puzzle of drugs prescribed for favor, etc.. --- Mark Cuban even talks about these middle men & his drug company price transparency. He says pricing transparency is #1 issue
Have posted several times with all of the ancillary benefits Leronlimab brings to the table --- Cytodyn advantages are so abundant, no need to "price gouge", ever. Again, we can not be priced out of a disease by a "competitor".
The world is going to love Cytodyn upon realizing LL & LL-PLS pricing to benefits, & Vs others.
No other non-toxic, non death inducing drug for any disease indication like our Leronlimab.
Ladies of Leronlimab MOA is the starting point.
May.
(11)
(0)
